Beth Conover, RN, MS; Jonathan C. Goldsmith, MD; Bruce A. Buehler, MD; Pierre A. Maloley, PharmD; Mary L. Windle, PharmD
This content is PDF only. Please click on the PDF icon to access.
Pentamidine isethionate is an aromatic diamidine-derivative antiprotazoal agent now being used in treating Pneumocystis carinii pneumonia in patients with immunodeficient disease states (1). The agent is usually administered by the intravenous or intramuscular route. Clinicians, however, have used aerosol preparations in an effort to target the respiratory tract during treatment and to decrease systemic side effects (2, 3). This route of administration presents health care providers with the potential for exposure to pentamidine, and concerns have been expressed that pregnant staff members might have associated adverse reproductive effects.
The Nebraska Teratogen Project addressed this concern, and unfortunately, little information is
Conover B, Goldsmith JC, Buehler BA, et al. Aerosolized Pentamidine and Pregnancy. Ann Intern Med. 1988;109:927. doi: https://doi.org/10.7326/0003-4819-109-11-927_1
Download citation file:
Published: Ann Intern Med. 1988;109(11):927.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use